Literature DB >> 30242813

Justice in CRISPR/Cas9 Research and Clinical Applications.

Clara C Hildebrandt1, Jonathan M Marron2.   

Abstract

CRISPR/Cas9 is a rapidly developing gene editing technology that will soon have many clinical applications. As with many other new technologies, somatic gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies by historically disenfranchised racial and ethnic minorities. We describe justice concerns related to CRISPR/Cas9, including its potential impact on historically mistreated populations through underrepresentation of minorities in genomic databases and the potential for disparate access to somatic gene therapies when they become clinically available. We then describe ongoing work that aims to address these justice concerns. We conclude by highlighting important considerations to ensure equitable access to therapies going forward, including enhancing diversity in genomic sequencing efforts, improving education and transparency, and building partnerships with underserved and socially disenfranchised communities.
© 2018 American Medical Association. All Rights Reserved.

Year:  2018        PMID: 30242813     DOI: 10.1001/amajethics.2018.826

Source DB:  PubMed          Journal:  AMA J Ethics


  4 in total

1.  The Meaning of Informed Consent: Genome Editing Clinical Trials for Sickle Cell Disease.

Authors:  Stacy Desine; Brittany M Hollister; Khadijah E Abdallah; Anitra Persaud; Sara Chandros Hull; Vence L Bonham
Journal:  AJOB Empir Bioeth       Date:  2020-10-12

2.  Structural Racism in the COVID-19 Pandemic: Don't Forget about the Children!

Authors:  Jonathan M Marron
Journal:  Am J Bioeth       Date:  2021-03       Impact factor: 14.676

3.  Researchers views about perceived harms and benefits of gene editing: A study from the MENA region.

Authors:  Sawsan Abuhammad; Omar F Khabour; Karem H Alzoubi
Journal:  Heliyon       Date:  2021-04-23

Review 4.  Promising Stem Cell therapy in the Management of HIV and AIDS: A Narrative Review.

Authors:  Usha Rani Kandula; Addisu Dabi Wake
Journal:  Biologics       Date:  2022-07-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.